Ovarian Neoplasms
📧 Sign up to get email alerts when something new happens for Ovarian Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2024-03-06EMA Withdrawn: Apealea (paclitaxel) — Inceptua AB
EMA withdrawal of Apealea (paclitaxel) by Inceptua AB for ovarian neoplasms.
-
EMA withdrawal · 2021-11-25EMA Withdrawn: Equidacent (bevacizumab) — Centus Biotherapeutics Europe Limited
Equidacent (bevacizumab) has been withdrawn from the market in the European Medicines Agency record.
-
EMA withdrawal · 2020-07-27EMA Application withdrawn: Doxorubicin Hydrochloride Tillomed (doxorubicin hydrochloride) — Laboratorios Tillomed Spain S.L.U
The EMA withdrew the application for doxorubicin hydrochloride from Laboratorios Tillomed Spain S.L.U. for several cancer indications includ…
-
EMA withdrawal · 2018-07-13EMA Withdrawn: Topotecan Teva (topotecan) — Teva B.V.
Topotecan Teva has been withdrawn from the market by Teva B.V., affecting indications in ovarian neoplasms, uterine cervical neoplasms, and …
-
EMA withdrawal · 2017-11-10EMA Application withdrawn: Kyomarc (bevacizumab) — Amgen Europe B.V.
The EMA withdrew the application for Kyomarc (bevacizumab) from Amgen Europe B.V., relating to several carcinomas and neoplasms.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2016-12-21EMA Application withdrawn: Zemfirza (cediranib maleate) — AstraZeneca AB
The EMA indicates the Zemfirza (cediranib maleate) application has been withdrawn by AstraZeneca AB for ovarian neoplasms.
-
EMA withdrawal · 2014-08-14EMA Application withdrawn: Neocepri (folic acid) — Endocyte Europe, B.V.
The EMA withdrew the application for Neocepri (folic acid) by Endocyte Europe, B.V., with therapeutic areas including ovarian neoplasms and …
-
EMA withdrawal · 2014-08-14EMA Application withdrawn: Folcepri (Etarfolatide) — Endocyte Europe, B.V.
EMA withdrawal of the Folcepri (Etarfolatide) application by Endocyte Europe, B.V. for indications in ovarian neoplasms and radionuclide ima…
-
EMA withdrawal · 2014-08-14EMA Application withdrawn: Vynfinit — Endocyte Europe, B.V.
The EMA withdrew the application for Vynfinit (Endocyte Europe, B.V.) for ovarian neoplasms.
-
CLINICAL_TRIALS withdrawal · 2010-04-27Clinical Trial Update: CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy [Phase 3]
A Phase 3 trial comparing Caelyx (pegylated liposomal doxorubicin) to paclitaxel HCl in epithelial ovarian carcinoma after failure of first-…
-
EMA withdrawal · 2010-03-22EMA Withdrawn: Paxene (paclitaxel) — Norton Healthcare Ltd.
Paxene (paclitaxel) is withdrawn from consideration by Norton Healthcare Ltd., affecting indications including sarcoma (Kaposi), non-small c…
-
EMA withdrawal · 2009-12-31EMA Withdrawn: Indimacis 125 (igovomab) — CIS bio international
EMA status indicates Indimacis 125 (igovomab) has been withdrawn from the market.
-
EMA withdrawal · 2009-12-31EMA Withdrawn: Evotopin (topotecan) — Beecham Group plc
EMA withdrawal of Evotopin (topotecan) from the market for ovarian neoplasms.